practicaldermatology.com
The first subject has been dosed in a first-in-human Phase 1 study of ATTO-1310, a novel, subcutaneous (SQ), half-life extended (HLE) anti-IL-31 biotherapeutic, Attovia Therapeutics announced.
ATTO-1310 is being evaluated as a potential systemic treatment for people living with pruritic conditions such as chronic pruritus of unknown origin (CPUO). Attovia said in a press release that it is committed to developing therapies for inflammatory and immune diseases that bring breakthrough efficacy to underserved patient populations, as well as offering excellent safety and high convenience. ATTO-1310, the company said, has the potential to achieve a best-in-disease therapeutic profile in pruritic disease with rapid and deep relief of itch, benign safety profile, and infrequent subcutaneous dosing.
“Chronic pruritus deeply affects millions of patients in the US and beyond, and there are currently no approved treatments for conditions like CPUO,” Dr. Hubert Chen, Chief Medical Officer of Attovia, said in the release. “ATTO-1310 has the potential to provide life-changing relief to patients suffering from these diseases. We are working with a group of international KOLs who have spent years advocating for the development of effective treatments for these patients, and who will help us drive progress in our clinical program. Advancement of ATTO-1310 into the clinic marks an important milestone for Attovia as we become a clinical-stage company delivering innovative therapies for patients with immune-mediated diseases.”
The Phase 1 study (NCT06787586) is a randomized, double-blind, placebo-controlled, multi-part, single-ascending dose and multiple-ascending dose study to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adult volunteers and patients suffering from pruritic disease.
Following closely behind ATTO-1310, Attovia is advancing four bispecific and multispecific programs for the treatment of immune-mediated diseases. This includes ATTO-3712, a first-in-class anti-IL-13 x IL-31, half-life extended bispecific that will be developed for the treatment of atopic dermatitis and other inflammatory conditions; ATTO-004, a multispecific in development for inflammatory bowel disease; and two discovery-stage programs with multi-disease treatment potential.